Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

rovi biotech ltd - enoxaparin sodium - solution for injection - 100mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

rovi biotech ltd - enoxaparin sodium - solution for injection - 100mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

rovi biotech ltd - enoxaparin sodium - solution for injection - 100mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

rovi biotech ltd - enoxaparin sodium - solution for injection - 100mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

rovi biotech ltd - enoxaparin sodium - solution for injection - 100mg/1ml

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 5 mg in 0.4 ml - arixtra® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. arixtra is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. arixtra is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. arixtra is contraindicated in the following conditions: - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.2) and use in specific populations (8.6).] - active major bleeding. - bacterial endocarditis. - thrombocytopenia associated with a positive in vitro test for anti-platelet antib

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

italfarmaco s.p.a - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. fondaparinux sodium injection is contraindicated in the following conditions:(4) - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.3) and use in specific populations (8.6).] - active major bleeding. - bacterial endocardi

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. fondaparinux sodium injection is contraindicated in the following conditions:(4) - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.3) and use in specific populations (8.6).] - active major bleeding. - bacterial endocardi

Panama - angļu - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh - enoxaparina sÓdica - enoxaparina sÓdica....100 mg.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -